On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

Hutchmed (China) is evaluating supply-chain options for a blood-cancer drug recently approved by Beijing to mitigate impact ...

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

Politico's Alice Miranda Ollstein discusses her latest reporting on how Health Secretary Robert F. Kennedy Jr.’s purge of ...

The mass layoffs of federal workers under Health Secretary Robert F. Kennedy Jr. have impaired data-gathering on critical ...

Outpatient administration of CAR T-cell therapies can reduce costs and improve patient satisfaction, with evolving ...

Health policy is crucial for advancing clinical research and ensuring accessibility and funding for novel therapies.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

A study by scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) introduces a more cost-effective, scalable ...